Drug intelligence / Profile preview

TippingPoint Biosciences DIPG program

Development stage: Preclinical
Lead developer: TippingPoint Biosciences
Modality: Small Molecules

Overview

TippingPoint Biosciences is developing a preclinical small-molecule therapeutic targeting aberrant chromatin states in Diffuse Intrinsic Pontine Glioma (DIPG), a rare and aggressive pediatric brain tumor. The company's platform focuses on modulating chromatin interactions to revert cancer cells from a pathogenic state. As of late 2024, the program is in the hit-to-lead stage, with plans to enter clinical trials by approximately 2028. The development is supported by funding from organizations including the Pediatric Brain Tumor Foundation and the American Cancer Society's BrightEdge.

Other names: DIPG programchromatin interaction modulator

Targets

H3K27M (Mutant histone H3 protein containing lysine-to-methionine substitution at position 27)

Beyond the preview

Go deeper on TippingPoint Biosciences DIPG program.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TippingPoint Biosciences DIPG program.

Explore the full profile